At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 62 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
In Brief
A Phase 1 clinical trial evaluating Pembrolizumab and Trebananib for Advanced Solid Tumor. Completed, enrolled 62 participants across 2 sites.
Detailed Summary
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Amgen
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartMay 2018
Primary CompletionDec 2024
TodayJul 2026
First PostedAug 3, 2017
Enrollment StartMay 1, 2018
Primary CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 8.9 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
Trebananibdrug
AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen